Simple Summary Hepatocellular carcinoma (HCC) is an aggressive human cancer and is
caused as consequences of chronic liver diseases. Although HCC is more common in …

The rising global prevalence of metabolic diseases has increased the prevalence of non-
alcoholic fatty liver disease (NAFLD), leading to an increase in cases of NAFLD-related …

Background and aims Atezolizumab plus bevacizumab and lenvatinib have not been
compared in a randomised controlled trial. We conducted a retrospective multi-centre study …

Abstract Background The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐
programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine …

Background A growing body of evidence suggests that non-viral hepatocellular carcinoma
(HCC) might benefit less from immunotherapy. Materials and methods We carried out a …

Introduction The best first-line treatment for patients with advanced hepatocellular carcinoma
(HCC) and Child–Pugh (CP) class B remains unknown. The aim of the present study was to …

Hepatocellular carcinoma (HCC) typically develops as a consequence of liver cirrhosis, but
HCC epidemiology has evolved drastically in recent years. Metabolic dysfunction …

Purpose This systematic review and meta-analysis reports on outcomes and hepatic toxicity
rates following stereotactic body radiotherapy (SBRT) for liver confined hepatocellular …

Non-alcoholic fatty liver disease (NAFLD), one of the most common causes of liver disease,
is an increasingly common cause of hepatocellular carcinoma (HCC). Several demographic …

Simple Summary Hepatocellular carcinoma is the fifth most common cancer worldwide. For
patients with advanced hepatocellular carcinoma, therapeutic options are limited. Lenvatinib …